VINIA
Commercial- Indications
- Cardiovascular health, Blood flow improvement
Company intelligence / Profile preview
VINIA®, the flagship red grape cell composition product, has demonstrated significant clinical efficacy in improving artery dilation and blood flow. It has over $50 million in cumulative sales since its US launch in May 2021. Clinical trials support heart-health claims with peer-reviewed publications. Additional products based on olive and pomegranate cells are under development or regulatory review for new markets
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioHarvest Sciences.